Fundz

Who to call at Safi Biotherapeutics, and when

Fundz watches for the moments Safi Biotherapeutics starts buying, and tells you who to reach.

  • An alert the day Safi Biotherapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Safi Biotherapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Safi Biotherapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Safi Biotherapeutics secures a $4.7 million extension to advance manufactured red blood cells toward its first clinical trial.

Nov 04, 2026
CambridgeManufacturingBiotechnologyHealth Care

Description

Safi Biotherapeutics announced a $4.7 million non-dilutive award extension to fund the final IND-enabling work before its first clinical trial. The funding will support core activities for the company's innovative mRBCs. This product aims to address the ongoing shortage of available blood supply. With this financing, Safi moves closer to a clinical trial submission planned for 2027.

Company Information

Company

Safi Biotherapeutics

Location

Cambridge, Massachusetts, United States

About

Safi Biotherapeutics is a developer of manufactured red blood cells (mRBCs) designed to serve as an alternative to donor blood transfusions. The company is focused on advancing bio-manufactured red blood cells with targeted immuno-phenotypes for various chronic transfusion indications. Launched in 2020, Safi is progressing the technology to demonstrate the feasibility of an allogeneic, stem-cell sourced mRBC product.

Related People

Tammy
Likely contact at this company
••••••••@••••••••

See Tammy's verified email →

Katie
Likely contact at this company
••••••••@••••••••

See Katie's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Safi Biotherapeutics's next move

Learn about Strategic plan

Safi Biotherapeutics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.